

### **DETAILED ACTION**

1. This Office Action is in response to Applicant's response and amendments filed 10/15/2007. Applicant has submitted new claims 82-97. Thus, claims 82-97 are examined.

2. Applicant's summary of the interview of 6/19/2007 is acknowledged.

### **EXAMINER'S AMENDMENT.**

3. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Christopher J. Nichols on 12/12/07.

### **In the claims**

4. Please amend the claims 82, 88, 91 and 92:

82 (Amended). An isolated polypeptide comprising:

a) the amino acid sequence of SEQ ID NO[.]: 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO[.]: 2;

wherein said sequence comprises a C122S SNP.

88. (Amended) An isolated polypeptide comprising an amino acid sequence at least 95% identical to

a) the amino acid sequence of SEQ ID NO[.]: 2 or

b) the amino acid sequence of amino acids 24 through 189 of SEQ ID NO[.]: 2;

wherein said sequence comprises a C122S SNP and said polypeptide exhibits at least one antiviral activity, antiproliferative activity, or immunomodulatory activity;

wherein said antiviral activity is against vesicular stomatitis virus or encephalomyocarditis virus;

wherein said antiproliferative activity is against TF-1 or Daudi Burkitt's cell line;

wherein said immunomodulatory activity is dendritic cell maturation, cytokine release by monocytes, CD4+ T-lymphocytes, or CD8+ T-lymphocytes.

91. (Amended) The polypeptide of claim 88, wherein said amino acid sequence is at least 97% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO[.]: 2.

92. (Amended) The polypeptide of claim 88, wherein said amino acid sequence is at least 99% identical to the amino acid sequence of amino acids 24 through 189 of SEQ ID NO[.]: 2.

5. Claims 82-97 are allowed.

#### **Contact Information**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jegatheesan Seharaseyon, Ph.D whose telephone number is 571-272-0892. The examiner can normally be reached on M-F: 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath N. Rao, Ph. D can be reached on 571-272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christine J Saoud/  
Primary Examiner, Art Unit 1647

JS  
Art Unit 1647  
December 31<sup>st</sup>, 2007.